A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's
Disease (AD) or Mild to Moderate AD.